BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19332867)

  • 1. Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma.
    Rolleman EJ; Weening J; Betjes MG
    Nephrol Dial Transplant; 2009 Jun; 24(6):2002-3. PubMed ID: 19332867
    [No Abstract]   [Full Text] [Related]  

  • 2. All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study.
    Vigneau C; Lorcy N; Dolley-Hitze T; Jouan F; Arlot-Bonnemains Y; Laguerre B; Verhoest G; Goujon JM; Belaud-Rotureau MA; Rioux-Leclercq N
    Nephrol Dial Transplant; 2014 Feb; 29(2):325-32. PubMed ID: 24302609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute cardiac failure after sunitinib.
    Machiels JP; Bletard N; Pirenne P; Jacquet L; Bonbled F; Duck L
    Ann Oncol; 2008 Mar; 19(3):597-9. PubMed ID: 18272908
    [No Abstract]   [Full Text] [Related]  

  • 4. Uncommon side effect with a commonly used targeted agent: sunitinib-induced nephrotic syndrome in a patient with metastatic renal cell carcinoma.
    Quintyne KI; Neenan T; Casserly L; Gupta R
    BMJ Case Rep; 2014 May; 2014():. PubMed ID: 24872478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?
    Winn SK; Ellis S; Savage P; Sampson S; Marsh JE
    Nephrol Dial Transplant; 2009 Feb; 24(2):673-5. PubMed ID: 19039026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyoderma gangrenosum with the use of sunitinib.
    Nadauld LD; Miller MB; Srinivas S
    J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
    [No Abstract]   [Full Text] [Related]  

  • 7. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma.
    Tsai KY; Yang CH; Kuo TT; Hong HS; Chang JW
    J Clin Oncol; 2006 Dec; 24(36):5786-8. PubMed ID: 17179114
    [No Abstract]   [Full Text] [Related]  

  • 8. Skin depigmentation induced by sunitinib treatment of renal cell carcinoma.
    Al Enazi MM; Kadry R; Mitwali H
    J Am Acad Dermatol; 2009 Nov; 61(5):905-6. PubMed ID: 19836653
    [No Abstract]   [Full Text] [Related]  

  • 9. Reversible posterior leukoencephalopathy syndrome induced by sunitinib.
    Martín G; Bellido L; Cruz JJ
    J Clin Oncol; 2007 Aug; 25(23):3559. PubMed ID: 17687168
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiac tamponade in a patient treated by sunitinib for metastatic renal cell carcinoma.
    Yıldız I; Varol U; Şen F; Kılıç L
    Anadolu Kardiyol Derg; 2014 Nov; 14(7):654-6. PubMed ID: 25163084
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Garfield DH; Hercbergs A; Davis PJ
    J Natl Cancer Inst; 2007 Jun; 99(12):975-6; author reply 976-7. PubMed ID: 17565154
    [No Abstract]   [Full Text] [Related]  

  • 12. A case of pyoderma gangrenosum possibly associated with sunitinib treatment.
    Ueharaguchi Y; Kabashima K; Sasahashi M; Matsuda A; Matubara K; Matsui M
    Int J Dermatol; 2013 May; 52(5):634-6. PubMed ID: 23590380
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Feldman DR; Martorella AJ; Robbins RJ; Motzer RJ
    J Natl Cancer Inst; 2007 Jun; 99(12):974-5; author reply 976-7. PubMed ID: 17565156
    [No Abstract]   [Full Text] [Related]  

  • 14. Reversible myocardial dysfunction in a young woman with metastatic renal cell carcinoma treated with sunitinib.
    Szmit S; Nurzyński P; Szaluś N; Opolski G; Szczylik C
    Acta Oncol; 2009; 48(6):921-5. PubMed ID: 19191048
    [No Abstract]   [Full Text] [Related]  

  • 15. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
    Rini BI
    Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to 'Thyrotoxicosis during sunitinib treatment for renal cell carcinoma' by Grossmann et al.
    Daniels GH
    Clin Endocrinol (Oxf); 2009 Sep; 71(3):455. PubMed ID: 19138312
    [No Abstract]   [Full Text] [Related]  

  • 17. Psychotic symptoms in the course of sunitinib treatment for advanced renal cell cancer. Two cases.
    Schellekens AF; Mulder SF; van Eijndhoven PF; Smilde TJ; van Herpen CM
    Gen Hosp Psychiatry; 2011; 33(1):83.e1-3. PubMed ID: 21353137
    [No Abstract]   [Full Text] [Related]  

  • 18. Sunitinib-aggravated hypertension.
    Rivera F; Benounna M; Sánchez de la Nieta MD
    J Hypertens; 2009 Jul; 27(7):1502-3. PubMed ID: 19542988
    [No Abstract]   [Full Text] [Related]  

  • 19. Sunitinib-induced hand-foot syndrome in a renal cell carcinoma: a sclerodermatous and rheumatoid arthritis-like case.
    Ohtsuka T
    J Dermatol; 2012 Nov; 39(11):943-4. PubMed ID: 22257303
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
    O'Donnell PH
    BJU Int; 2011 Oct; 108(8):1284-5. PubMed ID: 21418138
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.